California is currently home to 5613 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Precise Infliximab Exposure and Pharmacodynamic Control
Recruiting
Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment. The main reason for this research study is to determine if a computer program that calculates an individualized dose based on a patient's blood testing results (precision dosing) can better achieve the best... Read More
Gender:
ALL
Ages:
Between 6 years and 22 years
Trial Updated:
01/30/2025
Locations: Children's Hospital of Los Angeles, Los Angeles, California
Conditions: Crohn Disease
Direct Referral for Apnea Monitoring
Recruiting
The primary objective of this project is to compare a health care delivery model, Direct Referral for Apnea Monitoring (DREAM), with initial in-person (Traditional) clinic appointments for Veterans at risk for obstructive sleep apnea (OSA). A secondary objective is to determine the negative predictive value (NPV) of home sleep apnea testing (HSAT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: San Francisco VA Medical Center, San Francisco, CA, San Francisco, California
Conditions: Obstructive Sleep Apnea (OSA)
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Recruiting
This is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma. This is the first study to examine a naked anti-CD19 monoclonal antibody in relapsed CNS lymphoma patients as well as the combination of anti-CD19 antibody plus an Immunomodulatory imide drugs (IMiDs) in CNS lymphomas. This study will also test the novel hypothesis that Tafasitamab enhances blood-brain barrier permeability,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: CNS Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Recruiting
This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation design in patients with metastatic or unresectable gastro-esophageal cancer that are HER2-overexpressing (IHC 3+ or IHC2+/ISH+) and any other gastrointestinal cancer with HER2 expression with IHC3+. Patients must have progressed or been intolerant of at least one prior line... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Stanford Cancer Center, Palo Alto, California
Conditions: Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/30/2025
Locations: Loma Linda University Health, Loma Linda, California
Conditions: Spinal Muscular Atrophy (SMA)
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Recruiting
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California
Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
An Evaluation of the Effect of the Erchonia FX-405 Laser as an Adjunctive Treatment of Periodontitis
Recruiting
The purpose of this clinical study is to determine the effectiveness of the Erchonia® FX-405 (manufactured by Erchonia Corporation (the Company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease.
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
01/29/2025
Locations: 805 Dentistry, Thousand Oaks, California
Conditions: Periodontal Diseases, Periodontitis, Gum Disease
A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention
Recruiting
Genetic factors are a significant determinant of the likelihood of developing various types of cancers. Identification of germline risk can have important implications for both patients and their families. Although estimates vary, pathogenic germline variants can be seen in \~3-17.5% of unselected patients with cancer with important clinical significance. Unfortunately, despite progress in multigene testing and the identification of heritable conditions, genetic counseling and testing (GCT) rema... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Enloe Regional Cancer Center, Chico, California
Conditions: Solid Tumor, Adult
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients with Steroid-Refractory Acute Graft-versus-Host Disease
Recruiting
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-refractory.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/29/2025
Locations: Site 0191, Duarte, California
Conditions: Steroid Refractory GVHD
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients with KRAS-Mutant Metastatic Colorectal Cancer
Recruiting
This phase Ib trial tests the safety, side effects, and effectiveness of botensilimab, and balstilimab in combination with a fasting mimicking diet and high dose vitamin C in treating patients with KRAS-mutant metastatic colorectal cancer. Botensilimab and balstilimab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. KRAS is protein found on some tumor cells that is involved in the growth of tumor cells. KRAS mutant cells have been found to be more... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Los Angeles General Medical Center, Los Angeles, California
Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruiting
This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Exelixis Clinical Site #2, Fullerton, California
Conditions: Head and Neck Squamous Cell Carcinoma
A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors (OASIS)
Recruiting
This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab in adults with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: City of Hope, Duarte, California
Conditions: Solid Tumor, Adult